Vanda (VNDA) Ramps; Lazard Sees Upside

Shares of Vanda Pharmaceuticals (NASDAQ: VNDA) ramped on Friday. The move is being traced to "exceptionally positive" feedback for Vanda's experimental tasimelteon to treat non-24-hour disorder.

Feedback was pointed out by analyst Joshua Schimmer of Lazard Capital. He thinks Vanda is well ahead of the game in raising awareness about non-24 hour. He also sees plenty of upside in the stock.

Lazard has a Buy rating on Vanda Pharmaceuticals with a price target of $17.00.

For an analyst ratings summary and ratings history on Vanda Pharmaceuticals (NASDAQ: VNDA) click here. For more ratings news on Vanda Pharmaceuticals click here.

Shares of Vanda Pharmaceuticals closed at $7.12 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
• Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
• Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'